Mortality predictors and effects of antithrombotic therapies in atrial fibrillation: insights from ACTIVE-W

Area of Science:

• Cardiology
• Vascular Medicine
• Clinical Trials

Background:

• Antithrombotic therapies in atrial fibrillation (AF) primarily focus on preventing stroke and bleeding.
• The severity of non-fatal vascular and bleeding events can differentially impact mortality risk in AF patients.
• Understanding these differential impacts is crucial for optimizing treatment strategies.

Purpose of the Study:

• To evaluate the mortality risk associated with various non-fatal events in patients with atrial fibrillation (AF).
• To differentiate the impact of stroke severity and bleeding severity on subsequent mortality.
• To inform future research and clinical practice regarding risk stratification and prevention in AF.

Main Methods:

• Analysis of data from the Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events (ACTIVE)-W trial.
• Assessment of subsequent mortality risk following non-fatal ischemic and hemorrhagic strokes, and transient ischemic attacks.
• Evaluation of mortality risk associated with severe and major (but not severe) bleeding events, using hazard ratios (HR) and 95% confidence intervals (95% CIs).

Main Results:

• Non-fatal strokes, both ischemic and hemorrhagic, significantly increased mortality (HR 5.58).
• Disabling strokes (Rankin's score ≥3) markedly elevated mortality risk (HR 9.54), while non-disabling strokes did not.
• Severe bleeding events increased mortality (HR 3.35), but major bleeding events not classified as severe did not.

Conclusions:

• Non-fatal strokes, particularly disabling ones, are associated with increased mortality in AF patients.
• Only severe bleeding events, not all major bleeds, significantly increased mortality.
• Future research and clinical focus should prioritize preventing disabling strokes and severe bleeds in AF management.